Fgf6 in the adipose tissue has recently emerged as a potential therapeutic target in metabolic diseases (24), and we found that its expression was suppressed in the skeletal muscles of individuals with obesity. Here, FGF6 is linked to obesity due to melanocortin 4 receptor deficiency.